<DOC>
	<DOCNO>NCT01607398</DOCNO>
	<brief_summary>The study conduct respiratory specialist institute Japan , standardize technique data assurance check optimize data quality . The licensed dosage administration Adoair Japan apply study . Each subject receive treatment option randomize blinded fashion . Subjects randomize follow 4-week wash-out phase take either Adoair 50/250mcg twice daily placebo twice daily 12 week .</brief_summary>
	<brief_title>ADOAIR250 Anti-inflammatory Effects Japanese Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This randomise , double-blind , placebo-controlled , two-arm , parallel-group , 12-week-treatment study Japanese patient COPD . At Visit 1 , patient confirm fulfil inclusion criterion meet exclusion criterion start 4-week run-in period . During entire study period , include run-in period , drug allow use addition study drug oxitropium ( short-acting anticholinergic drug ) relief medication . At end run-in period ( Visit 2 ) , subject eligible randomisation evenly randomise one follow two treatment group start 12-week treatment period . - ADOAIR®250 one inhalation twice daily DISKUS inhaler - Placebo one inhalation twice daily DISKUS inhaler Study completers define subject complete examination , assessment , study procedure study period , include run-in period follow-up period . At completion/discontinuation treatment period , subject switch appropriate COPD treatment discretion investigator ( subinvestigator ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>1 . Japanese ( male female ) outpatient age 4080 year inclusive Visit 1 ( Female patient may enrol childbearing potential , childbearing potential agree properly use protocolspecified contraceptive measure . ) 2 . Have diagnosis COPD ( define per COPD guideline ) 3 . Have FEV1/FVC ratio &lt; 0.70 1560 minute follow use SALTANOL® INHALER 4 . Have FEV1 &gt; = 40 % &lt; 80 % predict normal value 1560 minute follow use SALTANOL® INHALER 5 . Current exsmokers smoke history least 10 packyears 6 . Able use DISKUS inhaler shortacting inhaled anticholinergic drug 7 . Capable provide write voluntary consent participate study 1 . Diagnosed investigator ( subinvestigator ) bronchial asthma 2 . Have respiratory disorder COPD ( e.g. , lung cancer , sarcoidosis , tuberculosis [ include old tuberculosis ] , pulmonary fibrosis ) 3 . Have chest Xray ( CT scan ) indicate diagnosis COPD might interfere assessment study ( This must assess use last imaging study perform within 6 month prior Visit 1 ; , chest Xray must obtain Visit 1 . ) 4 . Have chronic respiratory failure 5 . Have undergone lung volume reduction and/or lung transplant 6 . Have COPD exacerbation respiratory infection require systemic corticosteroid microbial therapy hospitalisation , within 6 week prior Visit 1 7 . Have use inhaled corticosteroid systemic corticosteroid within 4 week prior Visit 1 8 . Have use longacting β2 agonist ( inhaled patch ) within 2 week prior Visit 1 9 . Are unable stop shortacting β2 agonist therapy Visit 1 ( During study participation , oxitropium bromide ( TERSIGAN ) use relief medication . ) 10 . Receiving longterm oxygen therapy oxygen use 12 hour per day 11 . Have concurrent serious uncontrolled disease might interfere assessment study ( include psychiatric disease , unstable liver disease , heart disease ) 12 . Have QTc &gt; 450 msec ( &gt; 480 msec patient bundle branch block ) Visit 1 ( base average QTc three consecutive cardiac cycle ECG ) 13 . Have participate another study receive study drug within 4 week prior Visit 1 14 . Diagnosed investigator ( subinvestigator ) drug alcohol dependence 15 . Have know suspected hypersensitivity bronchodilator , inhale corticosteroid , lactose 16 . Have know α1 antitrypsin deficiency 17 . Previously enrol study 18 . Judged investigator ( subinvestigator ) inappropriate participate study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Japan</keyword>
	<keyword>COPD</keyword>
	<keyword>CAT</keyword>
	<keyword>placebo</keyword>
	<keyword>serum</keyword>
	<keyword>Adoair250</keyword>
	<keyword>anti-inflammatory</keyword>
	<keyword>sputum</keyword>
</DOC>